KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2016 - 2025)

Vertex Pharmaceuticals has reported Cash & Current Investments over the past 17 years, most recently at $6.6 billion for Q4 2025.

  • Quarterly results put Cash & Current Investments at $6.6 billion for Q4 2025, up 8.05% from a year ago — trailing twelve months through Dec 2025 was $6.6 billion (up 8.05% YoY), and the annual figure for FY2025 was $6.6 billion, up 8.05%.
  • Cash & Current Investments for Q4 2025 was $6.6 billion at Vertex Pharmaceuticals, up from $6.3 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for VRTX hit a ceiling of $11.9 billion in Q3 2023 and a floor of $5.8 billion in Q2 2024.
  • Median Cash & Current Investments over the past 5 years was $7.2 billion (2021), compared with a mean of $8.3 billion.
  • Biggest five-year swings in Cash & Current Investments: surged 65.23% in 2021 and later plummeted 48.42% in 2024.
  • Vertex Pharmaceuticals' Cash & Current Investments stood at $7.5 billion in 2021, then surged by 43.24% to $10.8 billion in 2022, then increased by 4.08% to $11.2 billion in 2023, then plummeted by 45.48% to $6.1 billion in 2024, then increased by 8.05% to $6.6 billion in 2025.
  • The last three reported values for Cash & Current Investments were $6.6 billion (Q4 2025), $6.3 billion (Q3 2025), and $6.4 billion (Q2 2025) per Business Quant data.